论文部分内容阅读
目的了解心包腔内化疗联合静脉化疗治疗恶性心包积液的疗效。方法采用Seldinger技术引流心包积液后进行心包腔内化疗,然后再行静脉化疗,分别统计心包积液的控制率、治疗相关副作用和生存时间。结果15例恶性心包积液,完全缓解14例,好转1例,控制率为100%;生存期2￣21个月,中位生存期11个月,未见严重副作用发生。结论心包腔内化疗联合静脉化疗治疗恶性心包积液疗效肯定,副作用较少。
Objective To investigate the efficacy of pericardial chemotherapy combined with intravenous chemotherapy in the treatment of malignant pericardial effusion. Methods Percutaneous transluminal pericardial effusion was induced by Seldinger’s technique. Peritoneal chemotherapy was followed. The control rate of pericardial effusion, treatment-related side effects and survival time were also calculated. Results 15 cases of malignant pericardial effusion, complete remission in 14 cases, 1 case of improvement, the control rate was 100%; survival of 2 to 21 months, the median survival of 11 months, no serious side effects. Conclusion Pericardial chemotherapy combined with intravenous chemotherapy for the treatment of malignant pericardial effusion is positive, with fewer side effects.